Previous 10 | Next 10 |
2024-05-09 11:39:53 ET More on Humacyte Humacyte, Inc. (HUMA) Q4 2023 Earnings Call Transcript Humacyte GAAP EPS of -$0.24 in-line Humacyte stock dips after pricing stock offering to raise $40.2M Seeking Alpha’s Quant Rating on Humacyte Histori...
DURHAM, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the first quarter ended March 31, 2024, on Frida...
2024-04-22 16:53:54 ET Gainers: Oportun Financial ( OPRT ) +5% . Humacyte ( HUMA ) +2% . Revance Therapeutics ( RVNC ) +2% . Office Properties Income ( OPI ) +2% . Axcelis Technologies ( ACLS ) +1% . Losers: C...
2024-04-19 10:58:19 ET Humacyte (NASDAQ: HUMA) stock price is pumping this week. It jumped by over 10% on Friday, continuing a spectacular rally that started last week. It has soared by 40% from its lowest point this month and is trading at its highest point since February 29th. The...
DURHAM, N.C., March 26, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced it will host a virtual KOL event on Thursday, March 28, 2024 at 8:00 ...
2024-03-22 12:05:25 ET Humacyte, Inc. (HUMA) Q4 2023 Earnings Conference Call March 22, 2024 08:00 AM ET Company Participants Lauren Marek - Investor Relations, LifeSci Advisors Laura Niklason - President and Chief Executive Officer Dale Sander - Chief Financial ...
2024-03-22 07:02:17 ET More on Humacyte Humacyte stock dips after pricing stock offering to raise $40.2M Humacyte gains on FDA priority review for bioengineered blood vessel Seeking Alpha’s Quant Rating on Humacyte Historical earnings data for Humacyte...
Bitdeer Technologies Group (BTDR) is expected to report $0.11 for Q4 2023 BioForce Nanosciences Holdings Inc (BFNH) is expected to report for Q4 2023 Casino Guichard Perrachon ADR (CGUSY) is expected to report for quarter end 2023-12-31 Motorsport Games Inc. (MSGM) is expected to repo...
2024-03-21 11:15:47 ET More on Humacyte Humacyte stock dips after pricing stock offering to raise $40.2M Humacyte gains on FDA priority review for bioengineered blood vessel Seeking Alpha’s Quant Rating on Humacyte Historical earnings data for Humacyte...
DURHAM, N.C., March 18, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the fourth quarter and year ended December 31,...
News, Short Squeeze, Breakout and More Instantly...
Humacyte Inc. Company Name:
HUMA Stock Symbol:
NASDAQ Market:
– BioVascular Pancreas (BVP) product candidate is under development as a potential treatment for type 1 diabetes – – Humacyte’s stem cell-derived islets observed to restore normal blood glucose in diabetic mice – – Non-human pri...
– Four unique ICD-10-PCS codes, effective October 1, 2024, for replacement of arteries in the upper and lower extremities using Humacyte’s HAV – – BLA submission under Priority Review by FDA for the treatment of vascular trauma, supported by Phase 2/3 clinica...
2024-05-30 12:06:59 ET Humacyte (NASDAQ: HUMA) stock price has surged hard since I wrote about it in April. It soared to a high of $9.35 on Thursday and is now trading at its highest point since December 2021. It has risen for seven straight weeks and is up by almost 370% from its l...